On June 12, 2024, Alida Biosciences (AlidaBio), an innovator in epigenomic research tools, announced it has completed a $7.5 million Series A financing. Genoa Ventures led the funding round with participation from FusionX Ventures and Vertical Venture Partners and is complemented by two ongoing Small Business Innovation Research grants of $4 million from The National Human Genome Research Institute. Wilson Sonsini Goodrich & Rosati advised Genoa Ventures on patent matters related to the transaction.

In addition to the Series A financing, AlidaBio also announced the Early Access launch of two products: the EpiPlex™ RNA Library Prep Kit and the EpiScout™ Analysis Suite. These products provide a comprehensive solution for multiplexed epitranscriptomic analysis of input-limited clinical research RNA samples, offering unprecedented sensitivity and accuracy. The additional capital from the financing will enable accelerated product development.

The Wilson Sonsini team that advised Genoa Ventures on patent matters related to the transaction includes Adam Cole, Maya Skubatch, and Julia Kennedy-Darling.

For more information, please see AlidaBio's news release. Additional coverage can be found on BioSpace.